Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends (Q36313699)

13 August 2017

1 reference

title

Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends (English)

1 reference

13 August 2017

Peter Hoffmann

1

1 reference

PubMed ID

16289936

13 August 2017

Barbara Warner

series ordinal

2

1 reference

PubMed ID

16289936

13 August 2017

language of work or name

1 reference

11 November 2005

1 reference

Journal of Pharmacological and Toxicological Methods

13 August 2017

1 reference

13 August 2017

53

1 reference

13 August 2017

2

1 reference

13 August 2017

87-105

1 reference

Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Cellular basis and mechanism underlying normal and abnormal myocardial repolarization and arrhythmogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Afterpotentials and triggered activity in hypertrophied myocardium from rats with renal hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Modulation of human erg K+ channel gating by activation of a G protein-coupled receptor and protein kinase C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Basic mechanisms underlying prenylamine-induced 'torsade de pointes': differences between prenylamine and fendiline due to basic actions of the isomers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Assessing predictors of drug-induced torsade de pointes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

HERG K(+) channel activity is regulated by changes in phosphatidyl inositol 4,5-bisphosphate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

T-wave alternans in LQTS: repolarization-rate dynamics from digital 12-lead Holter data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Cardiac channelopathies: from men to mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Cyclic AMP regulates the HERG K(+) channel by dual pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Desethylamiodarone prolongation of cardiac repolarization is dependent on gene expression: a novel antiarrhythmic mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Experimental models of torsade de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

KvLQT1 modulates the distribution and biophysical properties of HERG. A novel alpha-subunit interaction between delayed rectifier currents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

The impact of drug-induced QT interval prolongation on drug discovery and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Mechanisms of arsenic-induced prolongation of cardiac repolarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Effects of levobupivacaine, ropivacaine and bupivacaine on HERG channels: stereoselective bupivacaine block

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

The assessment of potential for QT interval prolongation with new pharmaceuticals: impact on drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Stereoselective cardiotoxic effects of terodiline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Rapid component I(Kr) of the guinea-pig cardiac delayed rectifier K(+) current is inhibited by beta(1)-adrenoreceptor activation, via cAMP/protein kinase A-dependent pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

I Kr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Pentamidine-induced long QT syndrome and block of hERG trafficking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Selective knockout of mouse ERG1 B potassium channel eliminates I(Kr) in adult ventricular myocytes and elicits episodes of abrupt sinus bradycardia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Drugs that induce repolarization abnormalities cause bradycardia in zebrafish

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: pharmacokinetic/pharmacodynamic model incorporating a site of adverse effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Potassium channel down-regulation in heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Modeling the heart--from genes to cells to the whole organ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Effects of bepridil on cardiac electrophysiologic properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Taking the "idio" out of "idiosyncratic": predicting torsades de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Drug-induced prolongation of the QT interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

From genes to channels: normal mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Predicting drug-hERG channel interactions that cause acquired long QT syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Refining detection of drug-induced proarrhythmia: QT interval and TRIaD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Dexamethasone rapidly induces Kv1.5 K+ channel gene transcription and expression in clonal pituitary cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Ziprasidone in the management of schizophrenia : the QT interval issue in context

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Adrenergic regulation of the rapid component of the cardiac delayed rectifier potassium current, I(Kr), and the underlying hERG ion channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Cytochrome P450 mono-oxygenase gene expression and protein activity in cultures of adult cardiomyocytes of the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Sudden cardiac death in heart failure. The role of abnormal repolarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Downregulation of delayed rectifier K(+) currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Bepridil differentially inhibits two delayed rectifier K(+) currents, I(Kr) and I(Ks), in guinea-pig ventricular myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Investigation of the potential of clozapine to cause torsade de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

P-glycoprotein inhibitors enhance saturable uptake of idarubicin in rat heart: pharmacokinetic/pharmacodynamic modeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

Impairment of human ether-à-go-go-related gene (HERG) K+ channel function by hypoglycemia and hyperglycemia. Similar phenotypes but different mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.07.003

10.1016/J.VASCN.2005.07.003

7 January 2021

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16289936